InflaRx N.V. (NASDAQ:IFRX) Sees Large Increase in Short Interest

InflaRx N.V. (NASDAQ:IFRX) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 6,039,577 shares, a growth of 203.1% from the April 30th total of 1,992,416 shares. Currently, 10.0% of the shares of the stock are short sold. Based on an average trading volume of 4,655,170 shares, the short-interest ratio is currently 1.3 days.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IFRX. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Oppenheimer initiated coverage on InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price for the company. Cantor Fitzgerald upped their target price on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Guggenheim reaffirmed a “buy” rating and issued a $14.00 target price on shares of InflaRx in a report on Tuesday, April 21st. Finally, Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $7.00 to $9.00 in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On InflaRx

Several institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its stake in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. HRT Financial LP purchased a new position in InflaRx in the fourth quarter valued at about $47,000. Concurrent Investment Advisors LLC raised its stake in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new stake in InflaRx in the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd bought a new stake in InflaRx in the 4th quarter valued at about $104,000. 42.39% of the stock is owned by institutional investors.

InflaRx Price Performance

Shares of IFRX traded up $0.02 during trading hours on Friday, hitting $2.40. The stock had a trading volume of 669,678 shares, compared to its average volume of 3,054,670. InflaRx has a 1-year low of $0.74 and a 1-year high of $2.95. The firm has a market capitalization of $173.50 million, a P/E ratio of -3.38 and a beta of 2.42. The firm has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.26.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Equities analysts predict that InflaRx will post -0.51 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.